Active transcutaneous bone conduction hearing implants: Systematic review and meta-analysis.

ABSTRACT:

Background

In July 2018 the active transcutaneous bone conduction hearing implant received FDA approval in the US (for patients 12 years and older with conductive and/or mixed hearing loss or single-sided deafness), reflecting the current trend of moving away from percutaneous hearing solutions towards intact skin systems.

Objectives

To critically assess the current literature on safety, efficacy and subjective benefit after implantation with an active transcutaneous bone conduction hearing device.

Data sources

Literature investigation was performed by electronic database search including PubMed and Cochrane Central Register of Controlled Trials, and manual search of relevant journals and reference lists of included studies.

Study eligibility criteria

Randomize

SUBMITTER: Magele A 

PROVIDER: S-EPMC6746395 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature